⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Official Title: Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE

Study ID: NCT06240143

Conditions

Melanoma

Study Description

Brief Summary: This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Amsterdam University Medical Center, Amsterdam, , Netherlands

Antoni van Leeuwenhoek Hospital, Amsterdam, , Netherlands

University Medical Center Groningen, Groningen, , Netherlands

Leiden University Medical Center, Leiden, , Netherlands

Erasmus University Medical Center, Rotterdam, , Netherlands

University Medical Center Utrecht, Utrecht, , Netherlands

Contact Details

Name: Christian Blank, Prof

Affiliation: Medical oncologist/researcher

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: